Global Fractionated Plasma Products Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Fractionated Plasma Products Market Insights, Forecast to 2034
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Plasma Fractionation.
Market Analysis and InsightsGlobal Fractionated Plasma Products Market
Global Fractionated Plasma Products market is expected to reach to US$ 32700 million in 2024, with a positive growth of %, compared with US$ 30330 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Fractionated Plasma Products industry is evaluated to reach US$ 50750 million in 2029. The CAGR will be 7.6% during 2024 to 2029.
The Blood Plasma Fractionation Product market is driven by the growing demand for plasma-derived therapies and the increasing prevalence of chronic and rare diseases. Plasma fractionation involves separating and purifying plasma components to produce therapies such as immunoglobulins, clotting factors, and albumin. The rise in awareness about the therapeutic benefits of plasma-derived products and the need for specialized treatments contribute to market growth as patients and healthcare providers seek effective solutions. Moreover, advancements in fractionation technologies, including improved product yields and safety profiles, align with better patient outcomes. However, the market also faces challenges, including ensuring a stable supply of plasma donors and addressing regulatory complexities related to plasma collection and product manufacturing. Additionally, competition from alternative therapies and addressing concerns about supply chain disruptions can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer innovative and safe plasma fractionation products, collaborate with healthcare professionals for therapeutic insights, and address the challenges to meet the increasing demand for specialized and life-saving plasma-derived therapies.
Report Covers
This report presents an overview of global Fractionated Plasma Products market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Fractionated Plasma Products market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Coagulation Factor
Immune Globulin
Albumin
Other
Immunology
Hematology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Fractionated Plasma Products introduction, etc. Fractionated Plasma Products Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Fractionated Plasma Products
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Fractionated Plasma Products Market
Global Fractionated Plasma Products market is expected to reach to US$ 32700 million in 2024, with a positive growth of %, compared with US$ 30330 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Fractionated Plasma Products industry is evaluated to reach US$ 50750 million in 2029. The CAGR will be 7.6% during 2024 to 2029.
The Blood Plasma Fractionation Product market is driven by the growing demand for plasma-derived therapies and the increasing prevalence of chronic and rare diseases. Plasma fractionation involves separating and purifying plasma components to produce therapies such as immunoglobulins, clotting factors, and albumin. The rise in awareness about the therapeutic benefits of plasma-derived products and the need for specialized treatments contribute to market growth as patients and healthcare providers seek effective solutions. Moreover, advancements in fractionation technologies, including improved product yields and safety profiles, align with better patient outcomes. However, the market also faces challenges, including ensuring a stable supply of plasma donors and addressing regulatory complexities related to plasma collection and product manufacturing. Additionally, competition from alternative therapies and addressing concerns about supply chain disruptions can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer innovative and safe plasma fractionation products, collaborate with healthcare professionals for therapeutic insights, and address the challenges to meet the increasing demand for specialized and life-saving plasma-derived therapies.
Report Covers
This report presents an overview of global Fractionated Plasma Products market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Fractionated Plasma Products market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Coagulation Factor
Immune Globulin
Albumin
Other
Segment by Application
Immunology
Hematology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Fractionated Plasma Products introduction, etc. Fractionated Plasma Products Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Fractionated Plasma Products
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports